| scholarly article | Q13442814 |
| P50 | author | Albin Fontaine | Q57298104 |
| Bruno Pradines | Q60044507 | ||
| Christophe Rogier | Q60048789 | ||
| Sébastien Briolant | Q60244022 | ||
| Thierry Fusai | Q114440111 | ||
| Joel Mosnier | Q114721458 | ||
| Eric Baret | Q114721466 | ||
| Marylin Torrentino-Madamet | Q114721472 | ||
| P2093 | author name string | Maud Henry | |
| P2860 | cites work | Salmonella enterica serovar Typhimurium requires nonsterol precursors of the cholesterol biosynthetic pathway for intracellular proliferation | Q35550354 |
| Mevinolin (lovastatin) potentiates the antiproliferative effects of ketoconazole and terbinafine against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies | Q35810617 | ||
| 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors lovastatin and simvastatin inhibit in vitro development of Plasmodium falciparum and Babesia divergens in human erythrocytes | Q35820841 | ||
| Role of P-glycoprotein in statin drug interactions | Q36634221 | ||
| Toxicity of statins on rat skeletal muscle mitochondria | Q40225246 | ||
| Activity, pharmacological inhibition and biological regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in Trypanosoma brucei. | Q41934019 | ||
| Active isoprenoid pathway in the intra-erythrocytic stages of Plasmodium falciparum: presence of dolichols of 11 and 12 isoprene units | Q42079385 | ||
| Characterization and regulation of Leishmania major 3-hydroxy-3-methylglutaryl-CoA reductase. | Q42091736 | ||
| The effects of protein farnesyltransferase inhibitors on trypanosomatids: inhibition of protein farnesylation and cell growth | Q42826831 | ||
| Plasmodium falciparum: the lethal effects of tunicamycin and mevastatin on the parasite are not mediated by the inhibition of N-linked oligosaccharide biosynthesis | Q43683370 | ||
| Iron chelators as antimalarial agents: in vitro activity of dicatecholate against Plasmodium falciparum | Q44088868 | ||
| Antifungal activity of fluconazole in combination with lovastatin and their effects on gene expression in the ergosterol and prenylation pathways in Candida albicans | Q44678465 | ||
| Validated HPLC-MS-MS method for simultaneous determination of atorvastatin and 2-hydroxyatorvastatin in human plasma-pharmacokinetic study | Q80149477 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Plasmodium falciparum | Q311383 |
| P304 | page(s) | 2654-2655 | |
| P577 | publication date | 2007-05-14 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparum | |
| P478 | volume | 51 |
| Q38938937 | Activity of Fluorine-Containing Analogues of WC-9 and Structurally Related Analogues against Two Intracellular Parasites: Trypanosoma cruzi and Toxoplasma gondii. |
| Q38852074 | Antileishmanial effect of mevastatin is due to interference with sterol metabolism. |
| Q35660950 | Aryloxyethyl Thiocyanates Are Potent Growth Inhibitors of Trypanosoma cruzi and Toxoplasma gondii. |
| Q40936537 | Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum |
| Q42929766 | Atorvastatin as a potential antimalarial drug: in vitro synergy in combinational therapy with dihydroartemisinin |
| Q41938814 | Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria |
| Q34669052 | Atorvastatin prevents Plasmodium falciparum cytoadherence and endothelial damage |
| Q35753471 | Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model |
| Q53684271 | Atorvastatin: In-Vivo Synergy with Metronidazole as Anti-Blastocystis Therapy. |
| Q28539314 | Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis |
| Q57157512 | Chemotherapy for Fighting Schistosomiasis: Past, Present and Future |
| Q37318751 | Design, synthesis and biological evaluation of WC-9 analogs as antiparasitic agents |
| Q33808801 | Diagnosis and management of the neurological complications of falciparum malaria |
| Q34574121 | Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth |
| Q44304870 | Effect of HMG-CoA reductase inhibitors on antimicrobial susceptibilities for gram-negative rods |
| Q36798357 | Impact of methylene blue and atorvastatin combination therapy on the apparition of cerebral malaria in a murine model |
| Q37152937 | Improvement of the efficacy of dihydroartemisinin with atorvastatin in an experimental cerebral malaria murine model |
| Q36018677 | In vitro antimalarial activity and drug interactions of fenofibric acid |
| Q33712676 | In vitro interaction of lumefantrine and piperaquine by atorvastatin against Plasmodium falciparum |
| Q93030858 | Primaquine derivatives: Modifications of the terminal amino group |
| Q43194042 | Proveblue (methylene blue) as an antimalarial agent: in vitro synergy with dihydroartemisinin and atorvastatin |
| Q42196224 | Short-term pretreatment with atorvastatin attenuates left ventricular dysfunction, reduces infarct size and apoptosis in acute myocardial infarction rats |
| Q43111774 | Simvastatin treatment shows no effect on the incidence of cerebral malaria or parasitemia during experimental malaria |
| Q43185216 | Statins alone are ineffective in cerebral malaria but potentiate artesunate |
| Q37190868 | Statins as potential antimalarial drugs: low relative potency and lack of synergy with conventional antimalarial drugs |
| Q46322657 | Target-similarity search using Plasmodium falciparum proteome identifies approved drugs with anti-malarial activity and their possible targets |
Search more.